Sensus Healthcare: 1,000 Machines, 450 Practices, One $38 Million Bet
Q3 revenue fell 13% and the stock is down 24% in 90 days — but the sequential inflection in gross margin is real, and the two private-equity groups just signed are the only number that matters now
SRTS · Earnings Call · 2026-11-12
The quarter that looks bad, and the one buried underneath it
Sensus reported $6.0 million of revenue against $6.9 million a year ago, a 13% decline. Read that alone and you'd file it under "broken small-cap device story." Read the composition and it's a different document. The $6.9 million base was heavily freighted with one customer: of the 16 systems shipped in Q3 2025, ten went to the historically largest account. This quarter that account bought zero — and revenue still only fell 13%. Stripping them out, both revenue and gross margin rose year-over-year and quarter-over-quarter by management's reckoning. More important is the sequence. The last two filed quarters were brutal: revenue troughed at $2 million in Q2 2026 with gross margin at 33.6%, down from $7 million and 39% a year prior. Then Q3 arrived at $6 million and roughly 55% gross margin. That is not a rounding error; that is a step change in both volume and unit economics occurring in a single quarter, and it is why gross margin is the number to watch here, not the year-over-year revenue print. Yes, some of it is accounting hygiene. Javier Rampolla was blunt: “8 of this quarter's systems were originally expected to ship in the second quarter but were delayed by third-party financing delays” — Javier Rampolla, Chief Financial Officer · 2026-11-12 — so 18 organic shipments, not 26. But 18 still beats 16, and the prior call had promised exactly this. Joe Sardano, in August: “Very clear, yes. ... So we're expecting a nice third quarter to come from all this.” — Joseph Sardano, Chairman and Chief Executive Officer · 2026-08-13 They delivered on units. Hold that credit.The genuinely new thing is not in the United States
Buried in the Q&A, Michael Sardano described a market that fails every intuition about where a $38 million company should be spending its time. Australia — now a fresh gainer in the company's keyword set as Australia, alongside New Zealand — is already cleared for SRT but has never been commercially pushed.Whether or not that gets sold, it reframes the international story. For years the international answer was China — the prior calls lean on China as "bread and butter," with Japan, Taiwan and Brazil queued behind MDSAP certification. Australia is different in kind: a reimbursement structure that is changing toward them, private-equity-backed groups with capital, and a 50-patients-a-day throughput claim on the machine. That is Asia Pacific as a specific addressable market rather than a slide. The domestic equivalent is the two private-equity-backed dermatology groups that signed in the quarter. Michael: “Between the 2 groups that are with us now, I think their footprint is about 450-or-more practices nationwide.” — Michael Sardano, President, Chief Commercial Officer and General Counsel · 2026-11-12 One took outright ownership, one took the shared-service model. Twenty-six units a quarter against 450 potential sites is the entire bull case expressed as arithmetic — and the entire bear case, too, because "hub and spoke" means the second system is not a repeat sale, it's a new persuasion.There's only 26 million people in Australia, but 30% of them will get skin cancer... In Australia, they barely have Mohs surgeons. There's only 600 total dermatologists in the entire country and only about 60 of them are actual Mohs surgeons. So they don't rely on that either. They just excise you.